Health Care/Hospital News & Press Release Distribution

RedHill Biopharma's RHB-204 Granted FDA Fast Track Designation for NTM Disease

TEL AVIV, Israel and RALEIGH, NC, Jan. 6, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or "the Company"), a specialty biopharmaceutical company, today announced that RHB-204 has been granted Fast Track designation by the U.S. Food and...

2021-01-06 20:24 5819

Eleva Secures up to EUR 60 million to Advance a Drug Candidate, Appoints New Board Member

FREIBURG, Germany, Jan. 6, 2021 /PRNewswire/ -- Eleva, a manufacturer of superior biologics, has secured up toEUR 60 million in funding from Zukunftsfonds Heilbronn (ZFHN). The funds will help advance one of its drug candidates, CPV-101, to stages that will facilitate further investment from ven...

2021-01-06 17:00 1776

Yiling Pharma expects to double its YoY net profit in 2020

SHIJIAZHUANG, China, Jan. 6, 2021 /PRNewswire/ -- Yiling Pharmaceutical, a Shenzhen stock market listed enterprise (002603.SZ), has recently published its 2020 earnings projection. The yearly net profit belonging to its shareholders is anticipated to be between 1.152 billion Chinese yuan and 1.27...

2021-01-06 16:55 6945

Seegene's COVID-19 test with saliva sample collection feature now available in Europe

SEOUL, South Korea, Jan. 6, 2021 /PRNewswire/ -- South Korea's biotechnology company specializing in molecular diagnostics, Seegene Inc. (KQ096530) said Tuesday that it has CE-IVD marked the saliva-based testing application for Allplex™ SARS-CoV-2 Assay and Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay...

2021-01-06 16:27 1836

Seegene's COVID-19 test with saliva sample collection feature now available in Europe

SEOUL, South Korea, Jan. 6, 2021 /PRNewswire/ -- South Korea's biotechnology company specializing in molecular diagnostics, Seegene Inc. (KQ096530) said Tuesday that it has CE-IVD marked the saliva-based testing application for Allplex™ SARS-CoV-2 Assay and Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay...

2021-01-06 15:45 1777

JOYSBIO's COVID-19 antigen test kit is capable of detecting the new SARS-COV-2 strain found in the United Kingdom and the United States

BINHAI, Tianjin, Jan. 6, 2021 /PRNewswire/ -- As the world watches a concerning new strain of SARS-COV-2 first identified in theUnited Kingdom, one global biotech company has announced that their antigen test kit can detect the variant. JOYSBIO Biotechnology Co.'s SARS-CoV-2 Antigen Rapid Test K...

2021-01-06 15:11 2412

Dr Ivan Puah Predicts 2021 To Be A Year Of Evolving Cosmetic Surgery & Lifestyle Changes In Singapore In The COVID-19 Era

SINGAPORE, Jan. 6, 2021 /PRNewswire/ -- It's been a year since COVID-19 disrupted lives and livelihoods. Prime Minister ofSingapore, Mr. Lee Hsien Loong, has recently announced that Singaporeans can expect the vaccines to be made available in early 2021. This good news brings much relief to th...

2021-01-06 14:27 1931

Dr Ivan Puah Predicts 2021 To Be A Year Of Evolving Cosmetic Surgery & Lifestyle Changes In Singapore In The COVID-19 Era

TurtleTree Labs, the global leader in cell based milk, launches TurtleTree Scientific

SAN FRANCISCO, Jan. 5, 2021 /PRNewswire/ -- TurtleTree Labs, the global leader in cell-based milk, today announced the launch of TurtleTree Scientific, dedicated to the growth of food grade growth factors. Despite the costs of producing cell-based meat declining over the years, the cell culture m...

2021-01-06 06:00 2024

TurtleTree Labs, the global leader in cell based milk, launches TurtleTree Scientific

New Resource for Survivors from NCCN Helps Guide Life After Cancer Diagnosis and Treatment

PLYMOUTH MEETING, Pennsylvania, Jan. 5, 2021 /PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®) announced the publication of new, free informational resources on health and wellness for cancersurvivors. These two newNCCN Guidelines for Patients® are focused on healthy livin...

2021-01-05 21:35 1566

New Resource for Survivors from NCCN Helps Guide Life After Cancer Diagnosis and Treatment

Connect Biopharma Establishes Scientific Advisory Board Comprised of Clinical Development and Program Indication Experts

Company's product development strategies to be enhanced by deep experience in dermatology, allergy and inflammatory diseases and successful drug approvals SAN DIEGO and TAICANG, SUZHOU, China, Jan. 5, 2021 /PRNewswire/ -- Connect Biopharma, a global clinical-stage biopharmaceutical company focuse...

2021-01-05 21:00 2129

Gift of Life Donor Program Leads U.S. in Organ Donation for 13th Consecutive Year

Region Demonstrates Extraordinary Generosity and Clinical Leadership Despite Pandemic Challenges: Most Organ Donors Every Year Since 2008 PHILADELPHIA, Jan. 5, 2021 /PRNewswire/ -- For the 13th consecutive year, Gift of Life Donor Program leads the nation in the most organ donors among all 58 U....

2021-01-05 20:43 3008

Gift of Life Donor Program Leads U.S. in Organ Donation for 13th Consecutive Year

Global Cord Blood Announces NHC Policy Update

HONG KONG, Jan. 5, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today reported thatChina's National Health Commission ("NHC") ...

2021-01-05 20:30 11518

Huami Enters in Definitive Agreement to Acquire a Minority Stake in Jiangsu Yitong High-Tech Co., Ltd. to expand the healthcare ecosystem for Chinese market

BEIJING, Jan. 5, 2021 /PRNewswire/ -- Huami Corp. (NYSE: HMI) today announced that it has entered into an agreement to acquired 29.99% of the outstanding shares of Jiangsu Yitong Hi-Tech Co., Ltd., (Shenzhen: 300211) for an aggregate consideration ofRMB959.68 million (US$147.08 million) in cash. ...

2021-01-05 20:05 10978

Chiauranib, an Anti-tumor Drug Developed by Chipscreen, is Given CDE "Breakthrough Therapy Designation"

SHENZHEN, China, Jan. 5, 2021 /RPNewswire/ -- Last December 25, the anti-tumor drug candidate Chiauranib, developed by Shenzhen Chipscreen Biosciences Co., Ltd., was granted with the "Breakthrough Therapy Designation Drug" by the Center for Drug Evaluation (CDE) and currently enter a phase III cl...

2021-01-05 17:49 2532

Bay Materials Obtains Patents to Protect Innovative Clear-Aligner Material Zendura™ FLX

FREMONT, California, Jan. 5, 2021 /PRNewswire/ -- Bay Materials LLC, a leader in high-performance thermoformable plastic materials for orthodontic clear aligner therapy (CAT), today announced that the U.S. Patent and Trademark office has allowed and issued its second patent for Bay's "Dual Shell ...

2021-01-05 17:15 2831

Terumo Enters 100th Anniversary Year

TOKYO, Jan. 5, 2021 /PRNewswire/ -- Terumo Corporation (TSE: 4543) is celebrating its 100th anniversary this year - marking 100 years of 'Contributing to Society through Healthcare' onSeptember 17, 2021. The company has established 'Stride Ahead' as a slogan, to celebrate and connect all Terumo ...

2021-01-05 15:00 11214

Y-Biologics signed License Agreement with 3D Medicines for T cell bispecific engager in Greater China territory

DAEJEON, South Korea and SHANGHAI, Jan. 5, 2021 /PRNewswire/ -- The South Korean biotech company Y-Biologics and theChina-based biopharmaceutical company 3D Medicines have entered into a License Agreement granting exclusive rights to develop, manufacture, and commercialize YBL-013, a T cell bi-sp...

2021-01-05 09:00 2364

Ascentage Pharma Announces its 9th Orphan Drug Designation from the US FDA in 2020, Setting a Record for Chinese Biopharmaceutical Companies

SUZHOU, China and ROCKVILLE, Md., Jan. 5, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug Adm...

2021-01-05 08:32 2618

Antengene Announces Submission of IND Application in China for a Global Phase 3 Trial of ATG-010 (Selinexor) in Advanced or Recurrent Endometrial Cancer

SHANGHAI and HONG KONG, Jan. 5, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncolo...

2021-01-05 08:00 3367

AGC Biologics Confirms Cell and Gene Therapy Commercial Expertise as Manufacturer of Orchard Therapeutics' Newly Approved Libmeldy(TM)

SEATTLE, Jan. 4, 2021 /PRNewswire/ -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), is the first manufacturer of Orchard Therapeutics' Libmeldy™, which was recently approved by the European Commission (EC) as a one-time therapy for ...

2021-01-04 22:30 3222